Spruce Biosciences, Inc. Stock Analysis & AI Score
Spruce Biosciences, Inc. (SPRB) has an ST Score of 46.1 (C+), driven by its Forecast (A) and held back by its Profitability (D+). Analysts rate it Buy with a $135.75 price target (+176.9% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Spruce Biosciences, Inc. (SPRB) has an ST Score of 46.1 (C+), driven by its Forecast (A) and held back by its Profitability (D+). Analysts rate it Buy with a $135.75 price target (+176.9% upside).
- Strongest
- ForecastA
- Weakest
- ProfitabilityD+
All factor grades
- ForecastA
- ValuationB
- Financial StrengthB-
- MomentumC
- GrowthC-
- ProfitabilityD+
- Piotroski2/9
Contact
SPRB stock: frequently asked questions
What is SPRB's ST Score?
Spruce Biosciences, Inc. (SPRB) has an ST Score of 46.1 (C+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is SPRB a buy, hold, or sell?
Analysts rate SPRB a Buy, with a price target of $135.75 (+176.9% vs the current price). Our ST Score grades it C+ (46.1/100). The ST Score is a data-driven signal, not a recommendation.
What are SPRB's factor grades?
Valuation B, Profitability D+, Financial Strength B-, Momentum C, Growth C-, Forecast A.
What is SPRB's valuation grade?
Spruce Biosciences, Inc. (SPRB) earns a valuation grade of B, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is SPRB's growth grade?
Spruce Biosciences, Inc. (SPRB) earns a growth grade of C-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is SPRB's profitability grade?
Spruce Biosciences, Inc. (SPRB) earns a profitability grade of D+, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is SPRB's financial strength grade?
Spruce Biosciences, Inc. (SPRB) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for SPRB?
The average analyst price target for Spruce Biosciences, Inc. (SPRB) is $135.75 from 11 analysts, which is +176.9% versus the recent price of $49.02.
What is SPRB's Piotroski score?
Spruce Biosciences, Inc. (SPRB) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.